Tretinoin can cause non-telogenhair loss in some men by inducing catagen-like changes in hairfollicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.
PP405 is a promising molecule that may reactivate dormant hairfollicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.